IPP Bureau
Briefs: Zydus, Divi's Laboratories and Relonchem
By IPP Bureau - November 17, 2025
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
WHO issues first global guidelines for managing diabetes in pregnancy
By IPP Bureau - November 17, 2025
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
EMA recommends authorization of Teizeild to delay Type 1 diabetes onset
By IPP Bureau - November 17, 2025
This is the first drug to receive a recommendation for this preventative indication in the European Union
FDA concludes Lupin’s Nagpur Unit-1 facility inspection with zero observations
By IPP Bureau - November 16, 2025
Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
By IPP Bureau - November 16, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr
By IPP Bureau - November 16, 2025
Total income for the period stood at Rs. 7101.28 crore
Medico Remedies gets GMP compliance certificate from SMDC, Ukraine
By IPP Bureau - November 16, 2025
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
Amcor launches ultra-light Shadow roll-on for next-gen beauty branding
By IPP Bureau - November 16, 2025
The new shadow roll-on delivers strong on-shelf presence with its modern rounded-base design
ALBIS unveils next-gen healthcare materials at COMPAMED 2025
By IPP Bureau - November 16, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Abbott unveils new diabetes care formula amid rising global diabetes crisis
By IPP Bureau - November 16, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Cenmed and Curavit team up to revolutionize clinical trial logistics
By IPP Bureau - November 16, 2025
This collaboration turns kitting into a strategic advantage for sponsors and sites
ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy
By IPP Bureau - November 16, 2025
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Merck to acquire Cidara Therapeutics for $9.2 billion
By IPP Bureau - November 15, 2025
Diversifying its portfolio to include late-phase antiviral agent
Zydus receives final approval from USFDA for Leuprolide Acetate injection
By IPP Bureau - November 15, 2025
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer
